Patent Expiry

Patent/Exclusivity Expiry: SEGLENTIS

Other upcoming events for ACAD

Phase 2 ReadoutPhase 2 Readout: remlifanserin
Phase 3 ReadoutPhase 3 Topline: A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Effi
Phase 3 ReadoutPhase 3 Topline: 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis
Phase 3 ReadoutPhase 3 Topline: A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
Phase 3 ReadoutPhase 3 Topline: A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia i

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: SEGLENTIS — ACAD Patent Expiry | BioSniper